Oxford Cannabinoid Holdings Plc is the holding company of Oxford Cannabinoid Technologies Ltd, a UK-based biotech company. We want to have a positive impact on the lives of people living with debilitating diseases and conditions and to change the narrative about cannabis for good. OCT has a range of compounds in drug development, including proprietary cannabinoid derivatives, phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system. This maximises the therapeutic potential of cannabinoids. With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCT’s team is committed to excellence. Together, we are passionate about delivering breakthrough therapies for life-threatening conditions with a significant unmet medical need. Follow our journey from early-stage discovery work to clinical trials as we continue to harness the therapeutic power of cannabinoids to develop new prescription medicines for people living with severe, chronic pain conditions and cancer.